NASDAQ: LPTX
Leap Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their LPTX stock forecasts and price targets.

Forecast return on equity

Is LPTX forecast to generate an efficient return?

Company
-125.27%
Industry
119.29%
Market
-46.52%
LPTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LPTX forecast to generate an efficient return on assets?

Company
-74.85%
Industry
46.9%
LPTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LPTX earnings per share forecast

What is LPTX's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.11
Avg 2 year Forecast
-$0.53
Avg 3 year Forecast
-$0.55

LPTX revenue forecast

What is LPTX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$39.4M
Avg 2 year Forecast
$81.9M
Avg 3 year Forecast
$120.7M

LPTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LPTX$0.24N/AN/A
OSRH$0.52N/AN/A
IMRN$1.82N/AN/A
APRE$1.69N/AN/A
BOLT$5.44$50.00+819.12%Buy

Leap Therapeutics Stock Forecast FAQ

What is LPTX's earnings growth forecast for 2025-2027?

(NASDAQ: LPTX) Leap Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.

Leap Therapeutics's earnings in 2025 is -$69,404,000.On average, 1 Wall Street analyst forecast LPTX's earnings for 2025 to be -$45,997,877, with the lowest LPTX earnings forecast at -$45,997,877, and the highest LPTX earnings forecast at -$45,997,877. On average, 1 Wall Street analyst forecast LPTX's earnings for 2026 to be -$21,962,950, with the lowest LPTX earnings forecast at -$21,962,950, and the highest LPTX earnings forecast at -$21,962,950.

In 2027, LPTX is forecast to generate -$22,791,741 in earnings, with the lowest earnings forecast at -$22,791,741 and the highest earnings forecast at -$22,791,741.

If you're new to stock investing, here's how to buy Leap Therapeutics stock.

What is LPTX's revenue growth forecast for 2029-2031?

(NASDAQ: LPTX) Leap Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.

Leap Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast LPTX's revenue for 2029 to be $1,633,960,628, with the lowest LPTX revenue forecast at $1,633,960,628, and the highest LPTX revenue forecast at $1,633,960,628. On average, 1 Wall Street analysts forecast LPTX's revenue for 2030 to be $3,393,068,635, with the lowest LPTX revenue forecast at $3,393,068,635, and the highest LPTX revenue forecast at $3,393,068,635.

In 2031, LPTX is forecast to generate $4,999,679,174 in revenue, with the lowest revenue forecast at $4,999,679,174 and the highest revenue forecast at $4,999,679,174.

What is LPTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LPTX) forecast ROA is -74.85%, which is lower than the forecast US Biotechnology industry average of 46.9%.

What is LPTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LPTX) Leap Therapeutics's current Earnings Per Share (EPS) is -$1.70. On average, analysts forecast that LPTX's EPS will be -$1.11 for 2025, with the lowest EPS forecast at -$1.11, and the highest EPS forecast at -$1.11. On average, analysts forecast that LPTX's EPS will be -$0.53 for 2026, with the lowest EPS forecast at -$0.53, and the highest EPS forecast at -$0.53. In 2027, LPTX's EPS is forecast to hit -$0.55 (min: -$0.55, max: -$0.55).

What is LPTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LPTX) forecast ROE is -125.27%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.